Until 2000, neuroblastoma was one of the deadliest tumours of childhood, with probabilities of long-term survival not ...
The FDA re-approved Wellcovorin, a drug from GSK, that the company stopped selling more than 25 years ago, as part of a push from the Trump administration to identify the causes of and potential ...
The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable ...
A team led by scientists at Harvard Medical School, Massachusetts General Hospital, and the Broad Institute of MIT and ...
Liver fibrosis, a pathological scarring process resulting from chronic liver injury, represents a significant global health ...
The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...
Six months ago, 4-year-old Jose Morales-Ortiz was struggling to say two-word sentences. Jose has severe autism, and he couldn ...
For decades, diagnosis of brain cancer has been medicine’s most difficult and hazardous challenge. Simple imaging such as MRI ...
KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved ...
During a live event, Adriana Rossi, MD, discussed easing CAR T-cell therapy access and highlighted cilta-cel's efficacy in earlier-line myeloma.
Researchers from Mass General Brigham and the Broad Institute of MIT and Harvard have identified genetic modifications that can improve the efficacy of chimeric antigen receptor (CAR)-T cell treatment ...
Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback